Literature DB >> 33652326

Functional benefits of co-occurring autistic symptoms in schizophrenia is delimited by symptom severity.

Margherita Bechi1, Ahmad Abu-Akel2, Giulia Agostoni3, Marta Bosia4, Federica Cocchi1, Marco Spangaro4, Roberto Cavallaro4.   

Abstract

BACKGROUND: Impairments in daily functioning characterize both autism spectrum disorder and schizophrenia. Research has shown that a subsample of schizophrenia patients presents autistic symptoms, leading to the hypothesis that their co-occurrence would be associated with a 'double dose' of deficit. A growing body of research examined this hypothesis by looking at the joint effect of autistic and positive psychotic symptoms, and yielded contrasting results, ranging from benefits to adverse effects. We hypothesized that the interactive effect of autistic and positive symptoms on functioning in schizophrenia might depend on the patients' symptom severity.
METHOD: In 170 schizophrenia patients, a two-step cluster analysis identified two groups of patients with different levels of autistic and positive symptom severity. Using general linear models, we examined the interactions of groups, autistic and positive symptoms on functioning.
RESULTS: Autistic and positive symptoms were interactively associated with better functioning, but only in the symptomatically less severe patients. In contrast, autistic and positive symptoms were independently associated with worse functioning in the symptomatically more severe patients. These associations were observed above and beyond the effects of I.Q. and illness duration.
CONCLUSIONS: The findings highlight the complex role played by co-occurring autistic symptoms in schizophrenia, whose beneficial effects on functioning appear to depend on patients' psychopathological severity. Our findings may help to reconcile the seemingly contrasting results from previous studies, and to understand the heterogeneity of behavior and functional outcomes in schizophrenia. This study underscores the potential utility of routinely assessing autism in schizophrenia, in order to better formulate individualized rehabilitative programs.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autistic symptoms; Diametric model; Functioning; Positive symptoms; Psychopathology; Psychosis

Mesh:

Year:  2021        PMID: 33652326     DOI: 10.1016/j.jpsychires.2021.02.044

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  4 in total

1.  Psychosocial functioning in the balance between autism and psychosis: evidence from three populations.

Authors:  Ahmad Abu-Akel; Stephen J Wood; Rachel Upthegrove; Katharine Chisholm; Ashleigh Lin; Peter C Hansen; Steven M Gillespie; Ian A Apperly; Christiane Montag
Journal:  Mol Psychiatry       Date:  2022-04-14       Impact factor: 13.437

2.  Get up! Functional mobility and metabolic syndrome in chronic schizophrenia: Effects on cognition and quality of life.

Authors:  Federica Cuoco; Giulia Agostoni; Silvia Lesmo; Jacopo Sapienza; Mariachiara Buonocore; Margherita Bechi; Francesca Martini; Ilaria Ferri; Marco Spangaro; Giorgia Bigai; Federico Seghi; Carmelo Guglielmino; Federica Cocchi; Roberto Cavallaro; Marta Bosia
Journal:  Schizophr Res Cogn       Date:  2022-03-02

3.  Autistic Symptoms in Schizophrenia: Impact on Internalized Stigma, Well-Being, Clinical and Functional Characteristics.

Authors:  Stefano Barlati; Gabriele Nibbio; Donato Morena; Paolo Cacciani; Paola Corsini; Alessandra Mosca; Giacomo Deste; Vivian Accardo; Valentina Regina; Jacopo Lisoni; Cesare Turrina; Paolo Valsecchi; Antonio Vita
Journal:  Front Psychiatry       Date:  2022-03-30       Impact factor: 4.157

4.  Assessment and correlates of autistic symptoms in Schizophrenia Spectrum Disorders measured with the PANSS Autism Severity Score: A systematic review.

Authors:  Gabriele Nibbio; Stefano Barlati; Irene Calzavara-Pinton; Nicola Necchini; Elena Invernizzi; Dario Dell'Ovo; Jacopo Lisoni; Giacomo Deste; Antonio Vita
Journal:  Front Psychiatry       Date:  2022-08-30       Impact factor: 5.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.